Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III enrollment progress, full ARCHER data, and CRD-38 clinical initiation – are key value drivers in…
On Thursday (September 11), Canadian Prime Minister Mark Carney revealed the first tranche of projects selected by the newly…
Gold’s record-setting price run continued this week, with yet another new all-time high in the books. Silver also fared…
Brings Company’s Total Claims to 491 in Area Housing the Only Rare Earths Producing Mine in U.S. Move Expands…
Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the ‘Company’ or ‘Bold’) is pleased to announce the results of a prospecting and…
Highlights: The latest drill results build on Bo_RC_14/25 drill hole (previously released as 12.0 metres @ 4.27% WO₃ from…
Altech Batteries (ATC:AU) has announced ALTECH – CERENERGY Battery Prototype Reaches Key Milestones Download the PDF here. This post…
Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the Toronto Stock Exchange later this month, the latest in a string…
Here’s a quick recap of the crypto landscape for Wednesday (September 10) as of 9:00 p.m. UTC. Get the…